520 related articles for article (PubMed ID: 23806302)
21. NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma.
Sui Q; Zhang J; Sun X; Zhang C; Han Q; Tian Z
J Immunol; 2014 Aug; 193(4):2016-23. PubMed ID: 25015826
[TBL] [Abstract][Full Text] [Related]
22. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
23. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
[TBL] [Abstract][Full Text] [Related]
24. Memory type 2 helper T cells induce long-lasting antitumor immunity by activating natural killer cells.
Kitajima M; Ito T; Tumes DJ; Endo Y; Onodera A; Hashimoto K; Motohashi S; Yamashita M; Nishimura T; Ziegler SF; Nakayama T
Cancer Res; 2011 Jul; 71(14):4790-8. PubMed ID: 21646476
[TBL] [Abstract][Full Text] [Related]
25. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
26. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
27. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
28. Metastasis-associated macrophages constrain antitumor capability of natural killer cells in the metastatic site at least partially by membrane bound transforming growth factor β.
Brownlie D; Doughty-Shenton D; Yh Soong D; Nixon C; O Carragher N; M Carlin L; Kitamura T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33472858
[TBL] [Abstract][Full Text] [Related]
29. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
[TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
31. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Melisi D; Ishiyama S; Sclabas GM; Fleming JB; Xia Q; Tortora G; Abbruzzese JL; Chiao PJ
Mol Cancer Ther; 2008 Apr; 7(4):829-40. PubMed ID: 18413796
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types.
Fujita T; Teramoto K; Ozaki Y; Hanaoka J; Tezuka N; Itoh Y; Asai T; Fujino S; Kontani K; Ogasawara K
Cancer Res; 2009 Jun; 69(12):5142-50. PubMed ID: 19491278
[TBL] [Abstract][Full Text] [Related]
33. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
36. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive cytolytic T cells for treatment of established mouse Renca tumors.
Qin W; Tian F; Wang F; Song B; Wang H; Zhang Q; Jovanovic B; Liang L; Guo Y; Smith N; Lee C
Urology; 2008 Oct; 72(4):943-7. PubMed ID: 18723212
[TBL] [Abstract][Full Text] [Related]
37. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III.
Naumann U; Maass P; Gleske AK; Aulwurm S; Weller M; Eisele G
Int J Oncol; 2008 Oct; 33(4):759-65. PubMed ID: 18813789
[TBL] [Abstract][Full Text] [Related]
38. Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer.
Bendle GM; Linnemann C; Bies L; Song JY; Schumacher TN
J Immunol; 2013 Sep; 191(6):3232-9. PubMed ID: 23940272
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor-beta controls T helper type 1 cell development through regulation of natural killer cell interferon-gamma.
Laouar Y; Sutterwala FS; Gorelik L; Flavell RA
Nat Immunol; 2005 Jun; 6(6):600-7. PubMed ID: 15852008
[TBL] [Abstract][Full Text] [Related]
40. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Rowland-Goldsmith MA; Maruyama H; Kusama T; Ralli S; Korc M
Clin Cancer Res; 2001 Sep; 7(9):2931-40. PubMed ID: 11555612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
